Johnson & Johnson (JNJ) Prepaid Assets (2009 - 2026)
Johnson & Johnson recorded quarterly Prepaid Assets of $4.8 billion in Q1 2026, up 16.01% quarter-over-quarter from $4.2 billion in Q4 2025, and up 17.77% year-over-year from $4.1 billion in Q1 2025.
Johnson & Johnson's Prepaid Assets history runs 18 years deep, the most recent figure standing at $4.8 billion for Q1 2026.
- In Q1 2026, Prepaid Assets rose 17.77% year-over-year to $4.8 billion; the TTM figure through Mar 2026 stood at $4.8 billion (up 17.77% YoY), while the FY2025 annual figure was $4.2 billion, up 1.66% from the prior year.
- Prepaid Assets came in at $4.8 billion for Q1 2026 at Johnson & Johnson, up from $4.2 billion in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $4.8 billion in Q1 2026 to a low of $2.4 billion in Q3 2023.
- A 5-year average of $3.9 billion and a median of $4.1 billion in 2025 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets tumbled 35.27% in 2023 and surged 82.69% in 2024, its largest moves.
- Johnson & Johnson's Prepaid Assets stood at $3.6 billion in 2022, then climbed by 25.67% to $4.5 billion in 2023, then declined by 9.5% to $4.1 billion in 2024, then rose by 1.66% to $4.2 billion in 2025, then advanced by 16.01% to $4.8 billion in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $4.8 billion, $4.2 billion, and $4.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 4.82 Bn |
| Dec 28, 2025 | 4.15 Bn |
| Sep 28, 2025 | 4.29 Bn |
| Jun 29, 2025 | 4.36 Bn |
| Mar 30, 2025 | 4.09 Bn |
| Dec 29, 2024 | 4.09 Bn |
| Sep 29, 2024 | 4.18 Bn |
| Jun 30, 2024 | 4.38 Bn |
| Mar 31, 2024 | 4.46 Bn |
| Dec 31, 2023 | 4.51 Bn |
| Oct 1, 2023 | 4.20 Bn |
| Jul 2, 2023 | 2.40 Bn |
| Apr 2, 2023 | 2.92 Bn |
| Jan 1, 2023 | 2.88 Bn |
| Oct 2, 2022 | 3.59 Bn |
| Jul 3, 2022 | 3.70 Bn |
| Apr 3, 2022 | 3.45 Bn |
| Jan 2, 2022 | 3.70 Bn |
| Oct 3, 2021 | 3.59 Bn |
| Jul 4, 2021 | 3.49 Bn |
| Apr 4, 2021 | 3.02 Bn |
| Jan 3, 2021 | 3.13 Bn |
| Sep 27, 2020 | 2.53 Bn |
| Jun 28, 2020 | 2.59 Bn |
| Mar 29, 2020 | 2.36 Bn |
| Dec 29, 2019 | 2.39 Bn |
| Sep 29, 2019 | 2.22 Bn |
| Jun 30, 2019 | 2.41 Bn |
| Mar 31, 2019 | 2.60 Bn |
| Dec 30, 2018 | 2.70 Bn |
| Sep 30, 2018 | 2.90 Bn |
| Jul 1, 2018 | 2.57 Bn |
| Apr 1, 2018 | 2.64 Bn |
| Dec 31, 2017 | 2.54 Bn |
| Oct 1, 2017 | 2.92 Bn |
| Jul 2, 2017 | 2.95 Bn |
| Apr 2, 2017 | 2.83 Bn |
| Jan 1, 2017 | 3.28 Bn |
| Oct 2, 2016 | 2.60 Bn |
| Jul 3, 2016 | 3.12 Bn |
| Apr 3, 2016 | 3.31 Bn |
| Jan 3, 2016 | 3.05 Bn |
| Sep 27, 2015 | 3.01 Bn |
| Jun 28, 2015 | 3.06 Bn |
| Mar 29, 2015 | 3.73 Bn |
| Dec 28, 2014 | 3.49 Bn |
| Sep 28, 2014 | 3.11 Bn |
| Jun 29, 2014 | 3.98 Bn |
| Mar 30, 2014 | 3.93 Bn |
| Dec 29, 2013 | 4.00 Bn |
| Sep 29, 2013 | 3.31 Bn |
| Jun 30, 2013 | 3.43 Bn |
| Mar 31, 2013 | 3.26 Bn |
| Dec 30, 2012 | 3.08 Bn |
| Sep 30, 2012 | 2.79 Bn |
| Jul 1, 2012 | 2.89 Bn |
| Apr 1, 2012 | 2.68 Bn |
| Jan 1, 2012 | 2.63 Bn |
| Oct 2, 2011 | 3.06 Bn |
| Jul 3, 2011 | 3.29 Bn |
| Apr 3, 2011 | 3.02 Bn |
| Jan 2, 2011 | 2.27 Bn |
| Oct 3, 2010 | 2.47 Bn |
| Jul 4, 2010 | 3.17 Bn |
| Apr 4, 2010 | 3.29 Bn |
| Jan 3, 2010 | 2.50 Bn |
| Sep 27, 2009 | 2.77 Bn |
| Jun 28, 2009 | 2.72 Bn |